As we expected, the prognostic data disclosed OS time, disease-specific survival (DSS) time, progression-free survival (PFS) time, and relapse-free survival (RFS) time was longer in HCC patients with a higher RAB11B expression, while those with a low RAB11B expression had a worse survival outcome (All p < 0.01, Figure 2I). This evidence concerns the gene RAB11B and hepatocellular carcinoma.